Company intelligence / Profile preview

LipimetiX

Natick, Massachusetts, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

AEM-28, their lead peptide candidate, showed significant lipid-lowering activity and positive effects on the artery wall in preclinical models and completed a Phase 1/2 clinical trial in refractory hypercholesterolemia, with evidence of pharmacodynamic activity[5][1].

Therapeutic areas: Cardiovascular
Modalities: PeptidesChimeric Apo E Mimetic Peptides
Industry: Biotech

Partnerships

Anji Pharmaceuticals (exclusive global licensee for Apo E mimetic peptide platform)

Beyond the preview

Go deeper on LipimetiX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LipimetiX.

Explore the full profile